Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • ARBs
ARBs versus Dihydropyridine CCBs : Which Protects the Heart and Which Safeguards the Kidneys?
Posted inCardiology Nephrology news Specialties

ARBs versus Dihydropyridine CCBs : Which Protects the Heart and Which Safeguards the Kidneys?

Posted by MedXY By MedXY 08/10/2025
Comparative review of angiotensin receptor blockers (ARBs, “沙坦”) and dihydropyridine calcium‑channel blockers (DHP‑CCBs, “地平类”) focused on organ protection—kidney, heart and brain—and practical selection based on comorbidity and evidence.
Read More
  • Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial
  • Challenging the Label: Large-Scale Meta-Analysis Refutes Most Statin-Attributed Adverse Effects
  • Tenecteplase Improves 90-Day Functional Outcomes in Basilar Artery Occlusion Within a 24-Hour Window: Results from TRACE-5
  • Beyond Symptom Resolution: Physiological Recovery Lags Behind Subjective Wellness in COVID-19 and Influenza
  • Early Inpatient Initiation of 1-Month TB Preventive Therapy Proves Non-Inferior for Patients with Advanced HIV and Cryptococcal Meningitis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in